24 September 2025

Cost-Utility Analysis of Acetylcholinesterase inhibitors in the Treatment of Mild to Moderate Alzheimer’s disease (in Thai language)

View Count

Share this research

Project Code 01-305-2550

Country

Thailand

Project Duration

Start : 1 January 2007

Research Status

Completed 100%

Complete Research Report

Quantity 0 files

Download Count

0 times

All research

24 September 2025

Cost-Utility Analysis of Acetylcholinesterase inhibitors in the Treatment of Mild to Moderate Alzheimer’s disease (in Thai language)

About Project

Content

The objective of this study is to estimate the cost-utility analysis of the cholinesterase inhibitors (i.e., donepezil, galantamine and rivastigmine) compared with no drug treatment in patients with mild to moderate alzheimer’s disease (AD) in Thailand based on the societal and governmental perspectives and to estimate the budget impact of the cholinesterase inhibitors when including these drugs on the national list of essential drugs (NLED) for precribing to mild to moderate AD patients. In addition, this study also investigates the experiences and perspectives of family caregivers and medical doctors in order to understand the overall context of AD in Thailand. The results can be used as a guideline or as data for health policy makers to determine which treatment should be included in the NLED to be given to mild to moderate AD patients.

Research Type

Others

Related Technologies

Pharmaceuticals

Funding Source

Thai Health Promotion Foundation (ThaiHealth)

Keyword / Search / TAG